文献速递中医内科中药与中成药合理使用

川芎方治疗偏头痛:高质量随机对照试验的系统评价与Meta分析

Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials.
PubMed 文献 · Front Pharmacol · 2018-06-27

该系统评价纳入19项高质量随机对照试验共1832例偏头痛患者,评价川芎方与安慰剂、常规药物治疗及联合治疗的疗效。Meta分析显示川芎方可减少偏头痛发作频率、持续时间、发作天数及疼痛严重程度,并提高总临床有效率(P < 0.05),不良事件发生率低。

要点

  • 川芎方可减少偏头痛发作频率、持续时间、发作天数及疼痛程度。
  • 川芎方可提高偏头痛总临床有效率(P < 0.05)。
  • 19项研究中16项报告不良事件监测,不良事件发生率低。

核心结论

  • 川芎方对偏头痛具有症状缓解作用。

研究设计与样本

  • 系统评价与Meta分析,检索英文和中文电子数据库至2017年3月。
  • 纳入Cochrane偏倚风险评分≥4的高质量随机对照试验,共19项、1832例参与者。
  • 采用Cochrane协作网偏倚风险评估工具评价方法学质量,RevMan 5.3软件进行Meta分析。

主要发现

  • 19项RCT中,川芎方对比安慰剂5项,川芎方对比常规药物治疗13项(15个比较),川芎方联合常规药物对比常规药物1项。
  • Meta分析显示川芎方可减少偏头痛发作频率、持续时间、发作天数及疼痛严重程度(P < 0.05)。
  • 川芎方可提高总临床有效率(P < 0.05)。
  • 19项研究中16项报告不良事件监测,不良事件发生率低。

临床怎么用

  • 可将川芎方作为偏头痛症状缓解的辅助治疗选择,但需结合患者具体情况。

局限性

  • 检索截止至2017年3月,未纳入此后发表的研究。
  • 仅纳入Cochrane偏倚风险评分≥4的RCT,可能排除部分质量较低但信息相关的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Migraine is a complex, prevalent and disabling neurological disorder characterized by recurrent episodes of headache without ideal treatment. We aim to assess the current available evidence of herbal Chuanxiong (Ligusticum chuanxiong Hort. root) formulae for the treatment of migraine according to the high-quality randomized controlled trials (RCTs). Methods: English and Chinese electronic databases were searched from their inceptions until March 2017. The methodological quality of included study was assessed by the Cochrane Collaboration risk of bias tool. RCTs with Cochrane risk of bias (RoB) score ≥4 were included in the analyses. Meta-analysis was conducted using RevMan 5.3 software. Publication bias was assessed by funnel plot analysis and Egger's test. Results: Nineteen RCTs with 1832 participants were identified. The studies investigated the Chuanxiong formulae vs. placebo (n = 5), Chuanxiong formulae vs. conventional pharmacotherapy (CP) (n = 13 with 15 comparisons), and Chuanxiong formulae plus CP vs. CP (n = 1). Meta-analysis indicated that Chuanxiong formulae could reduce frequency, duration, days and pain severity of migraine and improve the total clinical efficacy rate (P < 0.05). Adverse event monitoring was reported in 16 out of 19 studies and occurrence rate of adverse event was low. Conclusion: The findings of present study indicated that Chuanxiong formulae exerted the symptom reliefs of for migraine.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shan CS, Xu QQ, Shi YH, et al. Chuanxiong Formulae for Migraine: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. Front Pharmacol. 2018. PMID: 30013473. doi:10.3389/fphar.2018.00589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。